Mesoblast fuses Phase II
Tuesday, 28 April, 2009
Melbourne’s Mesoblast has received approval to being a Phase II trial of its allogeneic stem cell product NeoFuse in cervical spine fusion.
The trial, to be held at Melbourne’s Epworth Hospital, will compare NeoFuse with autograft. Twenty-four patients with irreversible, end-stage degenerative disc disease will take part in the randomised, controlled trial.
Mesoblast is also working on lumbar spinal fusion and on repair or regeneration of discs in patients with earlier stage disease.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
